Effects of Vitamin D Supplementation on Muscle Protein Synthesis (VIPER)

December 17, 2024 updated by: University of Exeter

Effects of Vitamin D Supplementation on Myofibrillar Protein Synthesis Rates in Rested and Exercised Muscle in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial

Background: Healthy adults maintain muscle tissue by continuously building up and breaking down muscle proteins throughout the day. Studies have shown that vitamin D (VitD) is essential for maintaining muscle mass by activating cellular pathways involved in building muscle via muscle protein synthesis (MPS). Although, various candidate molecules have been identified in animal models, it is not known whether these pathways are activated in humans. Interestingly, animal studies indicate that 20% of VitD is stored in human muscle cells, which may help maintain VitD sufficiency during winter in Northern latitudes when there is not much sunlight Objectives: We will investigate whether VitD supplementation increases the MPS response to feeding and exercise, VitD storage in muscle cells, and cellular pathways that are involved in healthy sedentary or moderately active adults.

Methods: Participants will consume either a placebo (sucrose) or the intervention (vitamin D3, 3000IU/day) for 12 weeks in a double-blinded randomised study. Before and after the intervention participants will have body composition measured. Blood and muscle samples will be taken before and after a bout of exercise and ingestion of 20 g protein in order to measure MPS.

Study Overview

Detailed Description

Recent in vitro studies have demonstrated an anabolic role of vitamin D directly targeting skeletal muscle via vitamin D receptors (VDR) present in myotubes [1,2,3]. However, this has yet to be translated to in vivo human models.

25-hydroxyvitamin-D (25OHD) is the primary circulating metabolite and reference measurement for vitamin D status. This may then either be converted to 24,25-dihydroxyvitamin D3 (24,25OHD) to prevent intoxication [4] or be activated in the kidneys to 1,25-dihydroxyvitamin D (1,25OHD)[5].

Evidence support a biological role for 1,25OHD in skeletal muscle[1-4,7]. With focus on muscle hypertrophy, a study demonstrated that 25OHD can also be activated to 1,25OHD in myotubes[8] and promote cell proliferation, growth and differentiation of myocytes in in vitro skeletal muscle cells[7,9-13]. The mechanisms proposed include (i) gene expression of endocytic receptors for vitamin D binding protein (VDP) (megalin/cubulin) on the muscle cell surface membrane and (ii) high affinity for VDP to bind to actin inside the muscle cell. Furthermore, epidemiological studies support a positive role for vitamin D in human muscle function[14-21] and mechanistic studies implicate intracellular 25OHD in the regulation of protein metabolism. Cell culture and in vivo animal models demonstrate that 25OHD activates anabolic cell signalling proteins of the mTORC1 pathway in response to anabolic stimuli[21,22], which translates into an increased stimulation of muscle protein synthesis[17]. Despite these exciting results from cell culture and in vivo animal studies, no study has replicated these findings in in vivo human models.

The length of the intervention in studies investigating the effects of vitamin D supplementation on muscle health outcomes and MPS varies between studies; however, evidence supports improvements in fast-twitch muscle fibres in elderly women[18], muscle strength in humans and animals and an increased in MPS in rats and mice following a minimum of 12 weeks intervention [22]. Thus, this study plans to have 12 weeks of intervention to ensure there is sufficient time for a physiologically effect to take place. Seasonal variations in blood 25OHD concentrations have been evaluated in Caucasians residing in Northern Ireland[4]. Thirty-four percent were deficient (<25nmol/L) in winter months[4]; however, despite insufficient sunlight in winter to synthesise vitamin D in skin, a significant proportion of a population resident in the same latitude, in Scotland, maintained blood 25OHD concentrations >50nmol/L[6]. These data and a recent review[8] suggest that humans have evolved a storage mechanism, which allows 25OHD, produced in the summer, to be conserved and used more efficiently in winter.

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Devon
      • Exeter, Devon, United Kingdom, EX1 2LU
        • University of Exeter

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy adults aged 18 - 45
  • Sedentary and moderately active (NDNS)

Exclusion Criteria:

  • Any diagnosed acute or chronic condition
  • Very active (NDNS)
  • On medication apart from contraceptive pill
  • Not taking vitamin supplementation for 30 days before enrolling
  • Not having been exposed to the sun (synthesising months - any country) in the previous 30 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Vitamin D
3000 IU/Day 12 weeks
Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding
Placebo Comparator: Placebo
Placebo one/day 12 weeks
Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fractional synthetic rate of amino acid incorporation into myofibrillar protein
Time Frame: 12 weeks x 4 time points
Fractional synthetic rate of amino acid incorporation into myofibrillar protein
12 weeks x 4 time points

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phosphorylated mTOR
Time Frame: 12 weeks x 4 time points
Phosphorylated mTOR response following 12 weeks intervention vs placebo
12 weeks x 4 time points
Total mTOR
Time Frame: 12 weeks x 2 time points
Total mTOR following 12 weeks intervention
12 weeks x 2 time points
Plasma amino acid kinetics
Time Frame: 12 weeks x 16 time points
Plasma amino acid kinetics in response to intervention vs. placebo
12 weeks x 16 time points
Glucose
Time Frame: 12 weeks x 16 time points
Glucose response to intervention vs. placebo
12 weeks x 16 time points
Insulin
Time Frame: 12 weeks x 14 time points
Insulin response to intervention vs. placebo
12 weeks x 14 time points
Leg press
Time Frame: 12 weeks x 1 x1
Leg press - strength
12 weeks x 1 x1
Leg extension
Time Frame: 12 weeks 1 x 1
Leg extension - Strength
12 weeks 1 x 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Raquel Revuelta Iniesta, PhD, University of Exeter

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2020

Primary Completion (Actual)

June 23, 2024

Study Completion (Actual)

October 23, 2024

Study Registration Dates

First Submitted

December 17, 2024

First Submitted That Met QC Criteria

December 17, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 17, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 201021/B/03

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Due to data protection - participants did not agree to IPD

Study Data/Documents

  1. Protocol and ethics can be shared on request
    Information identifier: 201021/B/03
    Information comments: Ethics documents and study protocol can be shared on request. Please contact PI Dr Raquel Revuelta Iniesta at r.revuelta-iniesta@exeter.ac.uk or the PHSS Ethics Committee at a.guy@exeter.ac.uk

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vitamin D Effects on MPS

Clinical Trials on 3000 IU per Day Spray

Subscribe